NCT05298813View on ClinicalTrials.gov

Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

September 29, 2021

Primary Completion Date

January 4, 2023

Study Completion Date

January 4, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

IBIO123

IBIO123 1 mg, 5 mg and 10 mg

OTHER

Placebo

Matching Placebo

Trial Locations (11)

2001

Newton Clinical Trial Centre, Newtown

4052

Durban International Clinical Research, Enhancing Care Foundation, Durban

4449

Clinical Research Institute of South Africa - CRISA, KwaDukuza

9301

FARMOVS, Bloemfontein

37900-512

Santa Casa de Misercórdia de Passos, Passos

20.241-180

Instituto Brasil de Pesquisa Clinica, Glória

89801-355

Clinica Supera Oncologia, Chapecó

05012-020

Instituto Brasileiro de Controle do Câncer / Sao Camilo Oncologia, Pompéia

09080-000

Pesquisare Saúde, Santo André

0002

Johese Clinical Research ZAH, Pretoria

0183

Jongaie Research, Pretoria West

Sponsors
All Listed Sponsors
lead

Immune Biosolutions Inc

INDUSTRY